Abstract
INTRODUCTION
Fasting induces small intestinal mucosal atrophy including increased epithelial permeability and com promised tight junctions, which can lead to bacterial translocation, particularly in patients receiving a prolonged course of total parenteral nutrition (TPN) [1, 2] . Many surgeons involved in nutritional support therapy desire the identification of bioactive substances that may be efficacious in protecting against intestinal injury during longterm TPN administration, particularly with respect to intestinal barrier function and subsequent septic complications. Fasting and other states of malnutrition are associated with increased reactive oxygen species (ROS) formation, which has been implicated in the loss of intestinal mucosal structure and function under conditions of inflammation, injury, and shock [3, 4] . In addition, these fasting states are also accompanied by depletion of the critical antioxidant glutathione (GSH), which functions to eliminate induced ROS in the intestinal mucosa [57] . Therefore, GSH is the most prevalent and important lowmolecularweight thiol in mammalian tissues [8] . As GSH deficiency in tissues is associated with increased oxidative stress, aging, and increased risk of numerous chronic diseases as well as fasting [9] , the maintenance of tissue levels of GSH is critical for maintaining health and preventing disease and agerelated biological insults.
GSH sources in the intestinal mucosa include intracellular synthesis, biliary supply, and dietary intake. The intestinal lumen receives a large quantity of hepatic GSH from biliary secretion [10] and dietary GSH from fresh fruits, vegetables, and many types of meat [11] . As the only enzyme of the γglutamyl cycle located on the outer surface of the plasma membrane, γglutamyl transpeptidase (GGT) plays a key role in GSH homeostasis by breaking down extracellular GSH and providing cysteine, the ratelimiting substrate for intracellular de novo GSH synthesis [12] . The two intracellular enzymes, γglutamylcysteine synthetase and GSH synthetase, catalyze intracellular GSH synthesis from glutamate, cysteine, and glycine, which are translocated into cells by amino acid transporters on the surface of the plasma membrane following the resolution of extracellular GSH by GGT. Intracellular GSH plays an important role in antioxidant defense and the regulation of pathways essential for in vivo homeostasis through its catalysis by glutathione Stransferase (GST) and glutathione peroxidase [9] . Studies of oral GSH supplementation in humans and laboratory animals have shown that the enhance ment of intestinal mucosal GSH levels by oral GSH supplementation under conditions in which intracellular GSH status is compromised (i.e., GSH deficiency-related biological insults) can restore tissue GSH and promote ROS metabolism [10, 13, 14] . Thus, it has been described that orally administered GSH acts as backup for GSH deficient tissue.
As an alternative, the ability to control extracellular redox provides another possible role for intestinal luminal GSH. Recent studies have shown that the thiol/ disulfide redox status in the extracellular compartment regulates the ROS that are generated primarily in the intracellular compartment and serve an important function in the activation of proteins and upregulation of antioxidant and detoxification systems [1517] . Fur thermore, many proteins including transporters, receptors, and enzymes present on the surface of the plasma membrane and located in extracellular fluids contain cysteine and methionine residues that are subject to oxidation. Accordingly, these proteins respond to variations in the extracellular thiol/disulfide redox environment, which can alter their activity [18] . Notably, recent demonstrations that treatment with GSH leads to a significant increase in the number of free sulfhydryls on the cell surface have led to the conclusion that extracellular GSH modulates the interaction between bacteria and epithelial respiratory cells and inhibits bacterial invasion into these cells [19] . We previously suggested that fasting for 23 d causes intestinal mucosal atrophy resulting from increased apoptosis in jejunal villi, nitric oxide (NO) and ROS production following elevated inducible nitric oxide synthase (iNOS) expression, and decreased cell proliferation in jejunal crypts [20] . Conversely, these apoptosis mediators are all suppressed by treatment with aminoguanidine, a selective iNOS inhibitor, with consequent mucosal recovery, suggesting that iNOS, which induces the production of ROS, is likely to constitute a significant upstream factor promoting fastinginduced apoptosis in enterocytes. Furthermore, refeeding repaired fastinginduced jejunal atrophy by inhibiting these apoptosis mediators, including ROS, and also showed an association between ROS inhibition and increased cell proliferation for decreasing intestinal mucosal atrophy [21] . Therefore, we hypothesized that protection against intestinal mucosal atrophy might be provided through the elimination of induced ROS in the intestinal mucosa by introducing an antioxidant such as GSH during a fasting period in rats.
Therefore, the objective of the present study was to investigate the effects of oral GSH administration on the manifestation of fastinginduced intestinal atrophy through the reduction of oxidative stress, with a particular focus on the possible participation of intra cellular GSH levels and GGT expression on the cell surface as parameters for de novo intracellular GSH synthesis.
MATERIALS AND METHODS

Animals and experimental design
The experimental protocol and design were approved by the Institutional Animal Care and Use Committee at the Life Science Center of Josai University. Male Wistar rats at 9 wk of age were purchased from SLC (Shizuoka, Japan) and housed in wirebottomed cages. The rats were placed in a room illuminated from 7:00 am to 7:00 pm (12:12h light:dark cycle). The animals were allowed free access to deionized water and standard rat chow (CE2, CLEA Japan) until the study began. At 10 wk of age, 59 rats were randomly divided into eight groups ( Figure 1 ). Each group received saline (SA) or GSH (50 or 500 mg/kg b.w./d) using oral gavage needles at 24, 48, and 72 h before fasting, including a normally fed control group and a normally fed control that received GSH, with the following fasting durations in each group: (1) SA + ad libitum (normal fed control); (2) SA + 48h fast; (3) SA + 72h fast; (4) 500 mg/kg GSH + ad libitum (normal fed control received GSH); (5) 50 mg/kg GSH + 48h fast; (6) 50 mg/kg GSH + 72h fast; (7) 500 mg/kg GSH + 48h fast; and (8) 500 mg/kg GSH + 72h fast. All rats received SA or GSH by oral gavage for 2, 26, and 50 h after fasting. The GSH (Setria ® reduced glutathione) used in this work was provided by Kyowa Hakko Bio Co., Ltd. The rats were weighed daily.
Collection of intestinal mucosa
After fasting, the rats were anesthetized and then euthanized by exsanguination. The entire small intestine was carefully removed and placed on ice. Then, 10 cm of tissue from the oral (duodenum) side was removed and the remainder of the intestine was divided into two segments: proximal (jejunum) and distal (ileum). The segments used in analyses comprised the jejunum from 3 to 5 cm distal to the duodenum [22] . Samples with a Figure 1 Experimental design. Rats were divided into eight groups, one of which was fed ad libitum, another of which was fed ad libitum and received oral glutathione (GSH), and six of which were administered saline (SA) or GSH orally prior to and after fasting. The large block arrows represent treatment with SA (closed gray arrow) and GSH (closed block arrow).
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and examined under a light microscope and a digital camera system. For each rat, 5 clearly dyed sections were chosen randomly and 5 random fields for each section were assessed (at 40 × magnification). The content of iNOS was quantitatively measured based on the average optical density using a digital camera and ImageJ software (National Institutes of Health, Bethesda, Maryland, United States) [26] . To assess cell proliferation in the crypt, the cell proliferation index was determined using conventional light microscopy of specimens immunohistochemically stained for 5BrdU [27] . Rats were intraperitoneally injected with 100 mg/kg 5BrdU prior to euthanasia. 
Jejunal nitrite concentrations
Nitrite concentrations in the jejunum were measured using a dedicated highperformance liquid chromato graphy (HPLC) system (ENO20; EiCom, Kyoto, Japan) [28] . Jejunal segments were homogenized with an equal volume of methanol and centrifuged for deproteinization at 12000 g at 4 ℃ for 5 min. The samples were then applied to the HPLC system. The nitrites and nitrates were separated using a reverse phase column (NOPAK; EiCom), after which nitrate was reduced to nitrite in a reduction column packed with copperized cadmium (NORED; EiCom). These nitrites were then mixed with the Griess reagent in a reaction coil and the change in absorbance was monitored at 540 nm.
DNA oxidation analysis
Oxidative stress in the jejunum was evaluated by quantifying 8hydroxydeoxyguanosine (8OHdG) present in DNA [29] . 8OHdG is a product of oxidative length of approximately 3 cm were fixed in 10% neutral buffered formalin for measurement of mucosal height and immunohistochemistry. The remaining segments were snapfrozen in liquid nitrogen and stored at 80 ℃.
Histopathological analysis of mucosal height and apoptotic index
Fixed tissue samples were embedded in paraffin and sectioned (23 μm thickness) prior to being stained with hematoxylin and eosin (H&E). Mucosal height (villous height plus crypt depth) was measured using a microscope (BX41; Olympus, Tokyo, Japan) and a digital camera system (Penguin 150CL; Pixera, San Jose, CA, United States). Mucosal height was measured for at least 30 villi per animal.
To detect enterocyte apoptosis in the jejunum, apoptotic index (AI) using conventional light microscopy of H&Estained specimens was used. We followed previously published methods [20, 23] . In brief, jejunal sections as used above for histopathological analysis were examined in a blinded manner for the typical attributes of apoptotic cells. We assessed 50 villuscrypt columns per rat. For each column, the number and position of apoptotic cells and the total number of cells were recorded. To account for the effects of fasting and GSH treatment on apoptosis, the average number of apoptotic cells in villi and crypts was determined along with AI. To identify the locations of apoptosis along the villi and crypts, AI distribution curves were constructed on the basis of group means, in which cell position vs AI was plotted at each position. Here, AI was defined as the total number of apoptotic cells at each cell position and is expressed as the percentage of the total number of cells counted at that cell position. Cell position 1 was set as the cell at the cryptvillus junction and the cell at the base of the crypt column for villus and crypt data, respectively.
Immunohistochemical assessment of iNOS expression and 5-bromo-2'-deoxyuridine (5-BrdU)-positive cells
Immunohistochemical staining was performed using a rabbit antiiNOS polyclonal antibody [24] . The specimens were dewaxed and treated for antigen retrieval by boiling in 10 mmol/L citrate buffer (pH 6.0) [25] . After being washed with PBS, the specimens were incubated in 6% hydrogen peroxide and nonspecific binding was blocked with a 20% goat serum solution in PBS. Specimens were subsequently incubated with an antiiNOS primary antibody (1:100; BD Transduction Laboratories, Lexington, KY, United States), except for the control sections, for which no primary antibody was used. A biotinylated goat antirabbit IgG (1:200; Vector Laboratories, Burlingame, CA, United States) was used as a secondary antibody. The sections were then treated using the VECTASTAIN Elite ABC Kit (Vector Laboratories), and reaction products were detected using color development with diaminobenzidine. Finally, the sections were counterstained with hematoxylin DNA damage following specific enzymatic cleavage after 8hydroxylation of the guanine base and is thought to constitute a marker of oxidative DNA damage, reflecting the DNA repair rate [30] . Jejunal DNA was purified using the DNA Extractor TIS Kit (Wako Pure Chemical Industries Ltd., Osaka, Japan) [31] . DNA samples were hydrolyzed to nucleosides by sequential incubation with 6 U of nuclease P1 (Wako) followed by 2 U of alkaline phosphatase (Wako). Hydrolysates were filtered through a VIVASPIN 500 MWCO 10000 filter (Sartorius Stedim Biotech, Gottingen, Germany). The levels of 8OHdG in the filtered samples were determined using an ELISA kit (Japan Institute for the Control of Aging, Shizuoka, Japan).
Jejunal GSH and GSSG concentrations
GSH and GSSG concentrations were measured by using a GSSG/GSH Quantification Kit (Dojindo Molecular Technologies, Inc., Rockville, MD, United States). Jejunal segments were homogenized with 5% sodium sulfosalicylate (Wako) and centrifuged to remove proteins. For each sample, the supernatant was added to a well to which coenzyme working solution and enzyme working solution had been previously added, and incubated at room temperature. Then, the sub strate working solution was added to the well and it was incubated at room temperature. The absorbance of samples and the GSH standard was measured at 405 nm using a microplate reader (TECAN GENios, Grodig, Austria). For measurement of GSSG, the supernatant was treated with masking solution and then added to a well as described above. The absorbance of samples and standard GSSG was measured at 405 nm.
Analysis of Ggt1 mRNA expression by semi-quantitative reverse transcription-PCR
Total RNA was purified using the TaKaRa RNAiso Reagent (TaKaRa Bio, Kusatsu, Japan). Reverse transcription (RT) PCR was performed with total RNA using the RNA PCR kit (AMV) Version 3.0 (TaKaRa Bio): 1 cycle at 42 ℃ for 30 min, 99 ℃ for 5 min, and 5 ℃ for 5 min for reverse transcription, and 30 cycles at 94 ℃ for 30 s, 60 ℃ for 30 s, and 72 ℃ for 1 min for PCR. The following primer pairs (synthesized by TaKaRa Bio) were used: Ggt1 forward primer, 5'ACCACTCACCCAACCGCCTAC3'; Ggt1 reverse, 5'ATCCGAACCTTGCCGTCCTT3' (product size: 317 bp) [12] . Expression of target mRNAs was measured relative to that of glyceraldehyde 3phosphate dehydrogenase (Gapdh), which was determined using the following primers: Gapdh forward, 5'GGCACAGTCAAGGCTGAGAATG3'; Gapdh reverse, 5'ATGGTGGTGAAGACGCCAGTA3' (143 bp, TaKaRa Bio ID: RA015380). A portion of each PCR mixture was electrophoresed on a 2% agarose gel in TrisborateEDTA buffer and DNA bands were visualized using ethidium bromide staining. PCR product intensity was measured using the Gene Genius Bioimaging System (Syngene, Cambridge, United Kingdom).
Statistical analysis
Statistical analyses were performed using SPSS ver. 22 for Windows. All values are expressed as the mean ± SE. Oneway analysis of variance (ANOVA) followed by a Bonferroni multiplecomparison test was used for analyzing the statistical difference between the fasting periods in SA or GSHtreated groups. Twoway ANOVA followed by a Bonferroni multiplecomparison test was used for analyzing the statistical difference between the SA and GSHtreated groups for the fasting periods. Statistical significance was accepted at P < 0.05. The statistical analysis of this study was performed by Uchida H, who acquired biostatistics expertise during his training in public health. Figure 2 shows body weight changes in SAtreated and GSHtreated rats. Decreases in body weight in both groups were observed along with fasting. Rats fasted for 48 and 72 h with SA treatment showed approximately 15% (P < 0.01) and 19% (P < 0.01) body weight loss, respectively, compared with normally fed controls. There was no difference in weight loss between the GSH treatments and the respective SA treated groups at each fasting period.
RESULTS
Body weight changes
Histological characterization of jejunal mucosal atrophy
Jejunal mucosal atrophy was assessed by jejunal mucosal height. Decreased jejunal mucosal height in both SA and GSHtreated rats was observed along with fasting ( Figure 3 ). Rats fasted for 48 and 72 h with SA treatment showed a significant decrease (P < 0.01) in mucosal height compared with normally fed controls. However, significant differences (P < 0.01) in jejunal mucosal height were found between the SA Fasting caused gradual decreases in body weight in both SA-and GSH-treated groups. There was no difference in weight loss between the GSH treatments and the respective SA-treated groups in each fasting period. Values represent the mean ± SE. b P < 0.01 vs the normally fed control. 7-8 rats were tested in each group. GSH: Glutathione; SA: Saline.
and GSHtreated rats with 48 and 72 h of fasting.
iNOS protein expression in the jejunum
As shown in Figure 4A , iNOS protein staining was localized almost exclusively in the mucosal epithelial monolayer in the 48 and 72h fasting periods compared with the normally fed controls, and a decreased level of staining occurred with GSH treatment. Quanti tative measurement using the average optical density revealed that this expression significantly increased following fasting for 48 and 72 h with SA treatment (P < 0.01), whereas GSH treatments significantly decreased the fastinginduced enhancement of jejunal iNOS protein expression (P < 0.05 vs SA at 48 h fasting, P < 0.01 vs SA at 72 h fasting; Figure 4B ).
Nitrite level in the jejunum
We next measured the levels of nitrite, which is a stable oxidation product of endogenous NO that is induced by iNOS. In SAtreated groups, fasting significantly increased the jejunal nitrite concentration with 48 and 72 h of fasting compared with the normally fed controls (P < 0.01; Figure 5 ). Conversely, GSH treat ments significantly decreased the fastinginduced enhancement of the jejunal nitrite concentration com pared with the respective SAtreated group for each fasting period (P < 0.01).
8-OHdG level in the jejunum
As we previously determined that fasting causes jejunal apoptosis via ROS production and induction of NO following increased iNOS expression, in the present study we measured levels of iNOS expression, nitrite (indicating NO production), and 8OHdG (as a marker of ROS presence). Consistent with the abovementioned changes in iNOS expression, fasting increased intestinal nitrite levels, whereas the degree of increase was significantly reduced by GSH treatment. Furthermore, the elevated jejunal 8OHdG levels observed after fasting were significantly diminished by both 48 h and 72 h of GSH treatment (P < 0.01 for 50 mg/kg GSH vs SA with 72 h of fasting, P < 0.05 for 500 mg/kg GSH vs SA with 72 h of fasting; Figure 6 ).
Evaluation of enterocyte apoptosis
Apoptosis was determined by histomorphometry, which is preferable to terminal deoxynucleotidyl transferase dUTP nickend labeling for quantitative assessment. Using histomorphometric assessment of jejunal cells, we evaluated the contribution of reduced apoptosis to the recovery from fastinginduced mucosal atrophy mediated by oral GSH treatment. The representative apoptosis changes as visualized by conventional light microscopy of H&Estained specimens are shown in Figure 7A . AI distribution profiles in the villi and the crypt are also shown in Figure 7B . From the AI distribution profiles, increased apoptosis in the lower half of the villus (cell positions 1 to 40) was evident with 48 and 72 h of fasting in the SAtreated groups, and this increase was diminished by GSH treatment. In the SA-treated groups, fasting significantly increased jejunal villus AI with 48 and 72 h of fasting compared with that in the normally fed controls (P < 0.01; Table  1 ). GSH treatment significantly decreased the fastinginduced enhancement of villus AI compared with that in the respective SAtreated group for each fasting period (P < 0.05 for 50 mg/kg GSH vs SA with 48 or 72 h of fasting, P < 0.01 for 500 mg/kg GSH vs SA with 48 or 72 h of fasting). From the AI distribution profiles, increased apoptosis in the lower two-thirds of crypts (cell positions 1 to 20) was evident with 48 and 72 h of fasting in the SAtreated groups ( Figure 7B ), and this effect was diminished by GSH treatment. In the SA-treated groups, fasting significantly increased jejunal crypt AIs with 48 and 72 h of fasting compared with the normally fed controls (P < 0.01; Table 1 ). GSH treatments significantly ameliorated the fastinginduced increase in crypt AI compared with the respective SAtreated group for each fasting period (P < 0.01).
Evaluation of cell proliferation
GSH is known to exhibit an important function related to the regulation of cell proliferation by protecting against the damaging effects of ROS [32] . To evaluate the effect of oral GSH administration on the reduced cell proliferation in fastinginduced jejunal mucosal atrophy, we assessed 5BrdU incorporation, a pro liferation indicator, in the jejunum. Although cell proliferation decreased with 48 and 72 h of fasting compared with that in the normally fed controls (P < 0.01; Figure 8 ), animals treated with GSH exhibited significantly higher levels of jejunal cell proliferation compared with those in the respective SAtreated group for each fasting period (P < 0.01 for 50 mg/kg GSH vs SA at 48 h fasting, and for 500 mg/kg GSH vs SA at 48 and 72 h fasting).
GSH and GSSG levels in the jejunum
GSH is one of the most important scavengers of ROS; additionally, GSH and oxidized GSH (i.e., GSSG) are used as markers of oxidative stress [33] . To evaluate GSH redox balance and GSH levels in the jejunum consequent to oral GSH administration during fasting, we assessed GSH and GSSG levels in the jejunum. Fasting significantly decreased the GSH concentration in the jejunum (P < 0.01; Figure 9A ). GSH treatment significantly further decreased the fastinginduced decreases in the jejunal GSH concentration for each fasting period (P < 0.01). Conversely, GSSG con centration in the jejunum was similar to that of normally fed controls except for the 500 mg/kg GSH treatment group with ad libitum feeding ( Figure 9B ).
Ggt1 mRNA expression in the jejunum
Fasting significantly increased Ggt1 expression in the jejunum at 48 h of fasting (P < 0.05) (Figure 10 ) whereas GSH treatment significantly reduced Ggt1 elevation at 48 h of fasting (P < 0.05, P < 0.01 for 50 mg/kg GSH, 500 mg/kg GSH vs SA at 48 h of fasting, respectively). A similar tendency was obtained for the 72h fasting group, although this difference did not reach statistical significance.
DISCUSSION
Previous reports have suggested the involvement of GSH in fastinginduced intestinal mucosal atrophy; in addition, fasting has been associated with increased ROS formation and depletion of the critical antioxidant GSH in the intestine [4, 6, 3436] . However, the roles of GSH in intestinal mucosal recovery from this condition as mediated by oral GSH administration have not yet been described. The objective of the present study was to investigate the effects of oral GSH administration on the development of fastinginduced intestinal atrophy, with a particular focus on the possible participation of intracellular GSH level and GGT expression on the cell surface as potential parameters of intracellular de novo GSH synthesis.
During fasting, the intestinal lumen receives very little or no GSH from two of the three primary sources, i.e., biliary secretion [10, 37] and dietary intake [11] . There fore, the overall GSH levels of the intestinal mucosa decrease during fasting because the remaining GSH source, intracellular GSH, is primarily synthesized from GSH in the intestinal lumen.
There is growing evidence that dysfunctional GSH homeostasis is involved in the etiology of several diseases. The previously reported conditions associated with GSH depletion include liver disease [38] , immune disorders [39] , neurodegenerative disease [40] , cardiovascular disease [41] , pulmonary disease [42] , arthritis, diabetes [43] , and the aging process itself [44] . Thus, oral supplementation with GSH to increase the depressed GSH level has been studied extensively as a potential means to prevent these diseases by countering the negative effects of oxidative stress, which is one of their underlying causes. Several studies have shown that GSH supplementation in laboratory animals is effective, with benefits including enhancement of immune function [45] and protection against carcinogenesis [46] . In addition, daily consumption of GSH supplements in humans was effective at increasing body compartment stores of GSH, which may be of importance as the maintenance of tissue levels of GSH might be critical for maintaining health and preventing disease as well as agerelated biological insults [47] . Thus, it has been suggested that orally administered GSH may act as a backup for intracellular GSH for GSHdeficient tissue. Therefore, the enhancement of intestinal mucosal GSH levels by oral GSH supplementation under conditions of intracellular GSH deficiency-related biological insults such as fasting may restore tissue GSH and promote ROS metabolism, thus facilitating the recovery from intestinal mucosal atrophy. Our previous studies suggested that fasting induced intestinal mucosal atrophy could be alleviated by directly inhibiting the fastingmediated NO production by iNOS and subsequent ROS enhancement associated with increased jejunal apoptosis via, e.g., iNOS inhibitor treatment [20] or refeeding [21] . Notably, an association was also observed between inhibition of ROS and increasing cell proliferation [21] . The intestinal epithelial layer is uniquely organized for rapid self renewal, which is achieved by the wellregulated processes of crypttovillus apoptosis and crypt stem cell proliferation. The intestinal epithelium sits at the interface between the intestinal mucosa and the intestinal lumen, and as such is prone to oxidative damage induced by luminal and intracellular oxidants. A previous study [16] reviewed the GSH/GSSG redox mechanism, which modulates intestinal cell transition through cell proliferation, differentiation, or apoptosis and can govern the regenerative potential of the intestinal mucosa. Therefore, we hypothesized that protection against intestinal mucosal atrophy could be provided by controlling apoptosis and cell proliferation through the elimination of induced ROS in the intestinal mucosa by orally administering an antioxidant such as GSH during fasting in rats. Here, we found that there was no difference in weight loss between fasting alone and oral GSH treat ment during fasting (Figure 2 ) with the GSH levels used for this study. Conversely, jejunal mucosal atrophy was significantly increased by fasting but was remedied by oral GSH treatment during fasting ( Figure  3) , with significantly greater improvement resulting from the high vs low GSH dose. Furthermore, because the etiology of fastinginduced intestinal atrophy was shown to comprise ROS genesis from the NO produced by iNOS [20, 21] , we measured iNOS protein expression in the jejunum. We identified an inverse relationship between intestinal mucosal atrophy and iNOS protein expression (primarily in the mucosal epithelial mono layer) associated with oral GSH treatment during fasting, most particularly with high levels of GSH administration (Figure 4 ). This is supported by our previous observations that iNOS inhibitor treatment during fasting and refeeding after fasting decreases fastinginduced atrophy and suppresses iNOS ex pression in the jejunum.
Oral GSH treatment during fasting inhibited the fastingmediated generation of the apoptosis me diators NO and ROS concomitant with decreased iNOS expression (Figures 5 and 6) . To determine the importance of apoptotic changes in the jejunum for intestinal recovery by oral GSH treatment ( Figure  7A ), we performed a histomorphometric assessment including AI score (Table 1) and distribution profiles d P < 0.01 vs the respective SA-treated group in each fasting period. 7-8 rats were tested in each group. GSH: Glutathione; SA: Saline. ( Figure 7B ). The increased AI recorded in the villi and crypts after fasting decreased with oral GSH treatment (Table 1) . Specifically, the lower half of the apoptotic enterocytes distributed across the entire jejunal villi and the apoptotic cells primarily located in the lower twothirds of the crypt ( Figure 7B ) were particularly affected by oral GSH treatment during fasting. These results were broadly consistent with changes in iNOS, NO, and ROS as apoptosis mediators, suggesting that oral GSH administration during fasting may inhibit enterocyte apoptosis by diminishing the ROS in the jejunum generated by fasting.
GSH treatment also was found to alleviate the decreased jejunal cell proliferation mediated by fasting (Figure 8) , with significantly greater improvement in fastinginduced jejunal mucosal atrophy resulting from high vs low dose GSH. These observations are consistent with the role of GSH in cell proliferation through protection against damage from ROS [16, 32] . Together, these findings indicate that oral GSH administration leads to less fastingmediated enhancement and therefore decreased overall ROS levels in the jejunal mucosa, thereby functioning to increase cell proliferation. This suggests that oral GSH administration may provide regenerative potential to the mucosa during fasting.
Notably, although our findings replicated prior results [6, 3436] that fasting significantly decreased jejunal GSH concentrations ( Figure 9A ), we found that the concentrations were further significantly decreased by oral GSH supplementation during fasting, with a greater effect from high vs low GSH dose. Conversely, the jejunal concentrations of the GSH oxidation pro duct GSSG were not changed by any feeding regime ( Figure 9B ). Furthermore, oral GSH treatment during fasting significantly decreased the fastinginduced ROS levels in the jejunum (Figure 6 ), but we consider it unlikely that this effect depends on antioxidant activity given the depressed GSH concentration in the jejunum. These results demonstrate that oral GSH administration during fasting did not contribute to the supply of GSH in the jejunum, and an increase in GSH oxidation was not observed, suggesting that oral GSH administration during fasting does not provide a backup for the jejunumdepleted GSH. The synthesis of intracellular de novo GSH, which is critical for ROS removal and maintenance of GSH homeostasis, relies upon the enzyme activity of the plasma membrane protein GGT to break down extracellular GSH [12] . In the present study, we demonstrated that oral GSH treatment significantly ameliorated the increased jejunal Ggt1 mRNA expression observed following 48 h of fasting ( Figure  10 ). In comparison, Jonas et al [4] indicated that fasting for 72 h did not change Ggt1 mRNA levels in the ileum, although this was determined via ribonuclease protection assay rather than by semiquantitative RT PCR as used in the present study. The different findings may also be a consequence of the disparity in fasting duration. Notably, Ogasawara et al [34] showed that starvation causes a striking decrease of GGT activity in the jejunum, which is consistent with our finding of fastinginduced increases in Ggt1 mRNA levels, as the mRNA expression of GGT might be upregulated by the decline of GGT activity [12] . Furthermore, Zhang et al [12] described that Ggt1 mRNA expression is increased during oxidative stress, which was considered to constitute an adaptation to such adverse conditions. Similarly, we found that fasting increased jejunal ROS levels and upregulated Ggt1 mRNA expression in the jejunum in this study. However, considering that oral GSH treatment during fasting significantly decreased both jejunal GSH concentration and Ggt1 mRNA expression, the supplemented GSH in the intestinal lumen may not be involved in intracellular de novo GSH synthesis.
The ability of GSH to control extracellular redox provides another possible role for intestinal luminal GSH during fasting, as the present study demonstrated that intracellular GSH levels of the jejunum mucosa were not increased by intestinal luminal GSH ad ministration during fasting, although the GSH ad ministration attenuated the fastinginduced ROS in the intestinal mucosa. Reversible redox reactions of intracellular thiol/disulfide pairs such as GSH/GSSG regulate diverse biological processes in vivo, including signaling for apoptosis and cell proliferation, enzyme catalysis, gene expression, and molecular folding and trafficking [1618, 48, 49] . Most studies have focused on the major intracellular thiols such as GSH [50, 51] ; however, relatively little is known regarding the effects of changes in extracellular thiol/disulfide pairs. Biliary GSH is an important intestinal luminal source of GSH and attenuates ROS of the intestinal mucosa by increasing the GSH levels of the intestinal mucosa. However, it has been suggested that biliary GSH controls the status of the intestinal lumen and contributes to protection of the intestinal mucosa [10] . The GSH of the intestinal lumen may act on the intestinal mucosa via both of these two pathways, and it is important to consider the control of the redox status of the intestinal lumen. In addition, the roles of extracellular (i.e., intestinal luminal) GSH in the recovery from fastinginduced intestinal mucosal atrophy enabled by oral GSH treatment have not yet been described.
A few studies have examined the ability of the extracellular thiol/disulfide redox state to regulate apoptosis and cell proliferation. Circu et al [16] de monstrated that the luminal/extracellular redox environment is determined by the cysteine/cystine (Cys/CySS) redox pair with contributions from the GSH system, with the majority of Cys in the intestinal lumen originating from GGT enzymatic hydrolysis of GSH obtained from dietary intake and biliary supply.
Intestinal cell proliferation and apoptosis are associated with quantitative changes in the redox potential (Eh) of the extracellular GSH/GSSG or Cys/CySS redox pair. In the present study, the changes in apoptosis and cell proliferation in the intestinal mucosa resulting from oral GSH administration during fasting may derive from Eh changes mediated by GSH and Cys in the intestinal lumen, which in turn may ultimately control signaling proteins, enzyme catalysis, and gene expression. For example, Devadas et al [52] linked ROS formation with the progression of Fasinduced apoptosis via the protective effects of extracellular GSH, which are ascribed to its known capacity as an antioxidant. Specifically, extracellular GSH was deduced to inhibit Fasmediated apoptosis following ROS reduction in cells because Fas crosslinking induced rapid generation of ROS well before the appearance of characteristic apoptotic changes. Furthermore, Fujise et al [22] suggested that fastinginduced apoptosis in the rat small intestine occurred via a receptor mediated type I apoptotic pathway including induced expression of FasL, Fas, and TNFR1. Selleri et al [53] and ViardLeveugle et al [54] provided evidence that iNOS expression and NO production are involved in the mechanism of FasL upregulation and Fasmediated apoptosis. The iNOSNOROSFasL pathway represents a potential link between the apoptosis and intestinal atrophy observed in the fasting.
In the present study, fastinginduced intestinal mucosal atrophy resulting from increased apoptosis was caused by increased production of NO and ROS as apoptosis mediators following elevation of iNOS expression. Because the iNOSNOROSFasL pathway is part of the apoptotic mechanism in the intestinal mucosa atrophy occurring after fasting [22, 5254] , oral GSH treatment during fasting might inhibit Fasmediated apoptosis following reduction of ROS levels in the jejunal mucosa resulting from Eh changes mediated by GSH and Cys in the intestinal lumen. Additionally, because iNOS protein expression was also induced by ROS produced from NO in fastinginduced intestinal mucosal atrophy in a previous study [20] , the decrease in ROS levels in the intestinal mucosa reduces iNOS protein expression and NO production. Moreover, Jonas et al [55] showed that the extracellular thiol/disulfide redox state modulates cell proliferation and that this system interacted with growth factor signaling in a human colon carcinoma cell line. Thus, the change in extracellular thiol/disulfide redox state in response to peptide growth factors indicated an interaction of growth factoractivated pathways and thiol/disulfide metabolism during intestinal cell proliferation. Therefore, oral GSH administration during fasting may regulate the redox state of the intestinal lumen and consequently may both relieve Fasmediated apoptosis and increase growth factormediated cell proliferation by ROS removal in jejunal epithelial cells (Figure 11 ). However, because our present study focused on intracellular GSH, further studies focusing on extracellular GSH are required to confirm this model. In particular, a study utilizing measurements of GSH/GSSG and Cys/CySS levels in the intestinal lumen along with Fas and growth factor signaling in the jejunum may be necessary to identify the mechanism underlying the recovery of the intestinal mucosal atrophy mediated by oral GSH administration during fasting.
In conclusion, oral GSH administration during fasting may provide regenerative potential to the jejunal mucosa through control of enterocyte apoptosis and cell proliferation. The GSH in the intestinal lumen provided through oral administration during fasting may not be involved in intracellular de novo GSH but may be useful to prevent intestinal mucosal atrophy by diminishing the levels of ROS in the jejunum generated by fasting.
COMMENTS
Background
Fasting induces small intestinal mucosal atrophy, which can lead to bacterial translocation, particularly in patients receiving a prolonged course of total parenteral nutrition (TPN), and is associated with increased reactive oxygen species (ROS) formation. This fasting state is also accompanied by depletion of the critical antioxidant glutathione (GSH), which functions to eliminate induced ROS in the intestinal mucosa. As GSH deficiency in tissues is associated with increased oxidative stress and fasting, the maintenance of tissue levels of GSH is critical for protection of small intestinal mucosa.
Research frontiers
The roles of GSH in intestinal mucosal recovery from fasting as mediated by oral GSH administration have not been investigated.
Innovations and breakthroughs
GSH treatment in the intestinal lumen could be a promising strategy to improve clinical outcome in patients receiving a prolonged course of TPN.
Applications
Oral GSH administration during fasting enhances jejunal regenerative potential to minimize intestinal mucosal atrophy by diminishing fasting-mediated ROS generation and enterocyte apoptosis and enhancing cell proliferation.
Peer-review
The manuscript by Uchida et al describes effects of oral GSH administration on fasting-induced intestinal atrophy in the small intestinal mucosa. The authors found that oral GSH administration of rats during fasting significantly enhanced jejunal regenerative potential to minimize mucosal atrophy. This reduction of intestinal atrophy correlated with correction of histopathological outcomes and many biochemical parameters. The authors' conclusion that oral GSH improves intestinal atrophy is supported by convincing results. Fasting causes increased production of NO and ROS as apoptosis mediators following elevation of iNOS expression. The changes in apoptosis and cell proliferation in the intestinal mucosa resulting from oral GSH administration during fasting may derive from intracellular ROS removal by redox potential changes mediated by GSH and Cys (originating from enzymatic hydrolysis of GSH) in the intestinal lumen. Intracellular ROS removal is considered to inhibit Fas-mediated apoptosis and increase growth factormediated cell proliferation. GSH: Glutathione; ROS: Reactive oxygen species.
